LSB Research Group LLC Dba Benchmark Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$233,344	38
2024	Research	$651,373	52
2023	Research	$4,758,134	215
2022	Research	$5,515,912	205
2021	Research	$1,730,839	51
2020	Research	$4,881,661	118
2019	Research	$1,033,665	81

Breakdown

Who paid Research payments · program years 2019–2025

Pfizer Inc. $18,621,327 722 payments
Eli Lilly and Company $104,848 6 payments
Eisai Inc. $53,425 29 payments
Veru Inc. $25,327 3 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $5,912,531 123 payments
A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $4,465,138 154 payments
A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $4,062,127 172 payments
A Phase 3 Randomized Placebocontrolled Observerblinded Trial to Evaluate the Safety of A 6Valent Ospabased Lyme Disease Vaccine Vla15 in Healthy Children 5 Through 17 Years of Age $1,567,227 79 payments
A Phase 1 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability and Immunogenicity of Selfamplifying Rna Vaccine Preparations Against Influenza in Healthy Individuals $1,077,490 41 payments
A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccinenaive Adults 18 Through 49 Years of Age $489,079 13 payments
A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccinenaive Adults 18 Years of Age and Older $189,619 19 payments
A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $177,378 41 payments
A Phase 12 Placebocontrolled Randomized Observerblind Dosefinding Firstinhuman Study to Describe the Safety Tolerability and Immunogenicity of A Respiratory Syncytial Virus RSV Vaccine in Healthy Adults $162,460 20 payments
A Phase 2B Placebocontrolled Randomized Observerblind Study to Evaluate the Safety Tolerability and Immunogenicity of A Respiratory Syncytial Virus RSV Vaccine When Administered Concomitantly With Tetanus Diphtheria and Acellular Pertussis Vaccine Tdap in Healthy Nonpregnant Women 18 Through 49 Years of Age $150,270 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.